宁泌泰胶囊治疗尿路感染对患者炎症反应水平和免疫功能的影响

目的探讨宁泌泰胶囊治疗尿路感染对患者炎症反应水平和免疫功能的影响。方法前瞻性选取2018年5月至2020年5月淮南新华医院收治的80例尿路感染患者作为研究对象,依据随机数字表法将患者分为宁泌泰组、常规组,每组各40例。2组患者均予以敏感抗生素进行治疗,联合组同时给予宁泌泰胶囊治疗,疗程2周。比较2组患者感染病原菌分布情况,治疗前、治疗后2周2组患者免疫功能指标、血清炎性因子指标、临床疗效。结果治疗前,2组患者外周血T淋巴细胞含量比较,差异均无统计学意义(P>0.05);治疗后2周,宁必泰组患者的外周血中CD3⁺、CD4⁺、CD4⁺/CD8⁺含量均高于常规组,CD8⁺含量低于常规组,差异有统计学意义(P<0.05)。治疗前,2组患者红细胞免疫指标比较,差异均无统计学意义(P>0.05);治疗后2周,宁必泰组患者的协同肿瘤细胞红细胞花环率(ATER)含量高于常规组,差异有统计学意义(P<0.05)。治疗前,2组患者白细胞介素-1β(IL-1β)、白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)、C反应蛋白(CRP)水平比较,差异均无统计学意义(P>0.05);治疗后2周,宁必泰组患者的IL-1β、IL-6、TNF-α、CRP水平均低于常规组,差异有统计学意义(P<0.05)。治疗后,宁必泰组患者的痊愈率、显效率、进步率分别为20.00%、75.00%、5.00%,优于常规组(55.00%、30.00%、12.50%),差异有统计学意义(P<0.05)。结论尿路感染患者抗感染治疗联合宁泌泰胶囊治疗具有一定的免疫调节作用,减轻炎症反应程度,对于提高临床效果具有重要意义。

Effect of Ningmitai Capsule in the treatment of urinary tract infection on patients'inflammatory reaction and immune function

Objective To explore the effect of Ningmitai capsule in the treatment of urinary tract infections on the level of inflammation and immune function in patients.Methods From May 2018 to May 2020,80 patients with urinary tract infection admitted to Huainan Xinhua Hospital were prospectively selected as research objects.They were divided into Ningbitai group and routine group according to random numbers,40 cases in each group.Both groups were treated with sensitive antibiotics,and Ningbitai group was given Ningbitai capsule at the same time,the course of treatment was 2 week.Distribution of infectious pathogens in the 2 groups,the changes of immune function index,serum inflammatory factor index and clinical efficacy before and 2 week after treatment were compared.Results There was no statistically significant difference in the distribution of infectious pathogens between the two groups of patients(P>0.05).Before treatment,there was no significant difference in the levels of T lymphocytes in the peripheral blood of the two groups(P>0.05);2 weeks after treatment,the levels of CD3⁺,CD4⁺,and CD4⁺/CD8⁺in the peripheral blood in the Ningbitai group were all higher than in the routine group,the level of CD8⁺was lower than that in the routine group,and the differences were statistically significant(P<0.05).Before treatment,there was no significant difference in the red blood cell immune indexes between the two groups(P>0.05);2 weeks after treatment,the content of associated tumor erythrocyte rossette(ATER)in the Ningbitai group was higher than that in the conventional group,the difference was statistically significant(P<0.05).Before treatment,there was no significant difference in the levels of interleukin-1β(IL-1β),interleukin-6(IL-6),tumor necrosis factor-α(TNF-α),C-reactive protein(CRP)between the two groups of patients(P>0.05);2 weeks after treatment,the levels of IL-1β,IL-6,TNF-αand CRP in the Ningbitai group were lower than those in the routine group,the differences were statistically significant(P<0.05).After treatment,the recovery rate,significant rate and progress rate of Nimbetha group were 20.00%,75.00%,and 5.00%,respectively,which were better than those of the conventional group(55.00%,30.00%,12.50%),and the difference was statistically significant(P<0.05).Conclusion The anti-infection treatment of patients with urinary tract infection combined with Ningmitai capsule treatment has a certain immunomodulatory effect,reduces the degree of inflammation,and is of great significance for improving the clinical effect.